Tuesday, November 29, 2022
Home Tags Biotech

Tag: biotech

Commentary: Special to the Business Journals

Utilizing an executive order to launch a National Biotechnology and Biomanufacturing Initiative, the Biden Administration aims to “drive biomedical innovation that supports the health...

Yonkers biotech ContraFect announces public offering of common stock

The company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the offering.

Keeping Pace: Job readiness is Pace University’s mission

Pace University President Marvin Krislov says, the school is "redoubling our offerings in the bioscience sector. We see that as encompassing three distinct but related areas: health care, technology and the life sciences."

Multiple Myeloma Research Foundation launches investment fund

The new $50 million fund will be a self-sustaining entity.

Land lease signed for $1.2B North 60 biotech project in Valhalla

In addition to the 60 acres of county-owned land, Fareri Associates will use the 20 acres of adjacent land it owns for the project.  The county expects to receive about $7 million in rent each year.

County Executive George Latimer questions Playland deal; examines other county assets

https://www.youtube.com/watch?v=alsZ8ogMnuY “We don’t believe it’s the best deal for the taxpayers of Westchester County,” County Executive George Latimer told members of The Business Council of...

ContraFect names Michael Messinger CFO

Prior to joining the company in 2012, Messinger was director of finance at Lexicon Pharmaceuticals in Texas.

Regeneron co-founder talks drug process, importance of science

New York Medical College recently hosted a seminar featuring Dr. George D. Yancopoulos, founding scientist, president and chief scientific officer of the major biotech company.

Collaboration guides researchers at University of Bridgeport biomedical center

"We are about 4,000 square feet, and sometimes it is so crowded," said Ruba Deeb, director of biomedical research development.

Westport’s Intensity Therapeutics optimistic about potential cancer treatment

The targeted treatment is designed to work on breast, colon, pancreatic, liver, lung and other cancers that do not respond to conventional treatments.

Acorda patents ruled invalid for MS drug Ampyra

The Ardsley biotech company faces competition from generic manufacturers after a judge ruled four of five patents invalid for Acorda's top-selling drug brand Ampyra.

Cara Therapeutics announces proposed offering of common stock

The company focuses on developing and commercializing new chemical entities designed to alleviate pain and pruritus.

Greenwich pharmaceutical company expands with Swiss biotech acquisition

Greenwich pharmaceutical service provider, Aptuit expands with acquisition of Swiss biotech company, Exquiron.

Column: Biotech investment offers promise, pitfalls

While the rewards can and have been high for investing in biotech stocks, this is not for the faint of heart.

Two health care startups join BioInc@NYMC

A therapeutic product research business and a telehealth services company are new tenants at the biotechnology incubator at New York Medical College.